- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02469532
DANCE Partner: Inflammatory Biomarker Analysis by Femoropopliteal Revascularization Method and Treatment Outcomes
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This is a prospective, multi-center, observational registry to document the baseline, 24-hour and 30-day inflammatory response and procedural outcomes out to 12 month follow-up after femoropopliteal angioplasty or atherectomy-based revascularization procedures.
- To observe the femoropopliteal revascularization outcomes post-angioplasty and/or atherectomy and to observe potential correlation between patency outcomes and the levels of MCP-1, C-reactive protein and MMP-9 from baseline to 24 hours and 30 days post-procedure.
- To provide a comparator dataset to the investigational DANCE trial, which has the same enrollment criteria as this observational trial but includes the investigational use of a local drug therapy to limit inflammation caused by mechanical revascularization.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72211
- Arkansas Heart Hospital
-
-
Louisiana
-
Bossier City, Louisiana, Stati Uniti, 7111
- Endovascular Technologies (Willis Knighton Medical Center)
-
-
Mississippi
-
Hattiesburg, Mississippi, Stati Uniti, 39401
- Hattiesburg Clinic
-
-
North Carolina
-
Raleigh, North Carolina, Stati Uniti
- Rex Hospital
-
-
Texas
-
New Braunfels, Texas, Stati Uniti, 78130
- Mission Research Institute
-
Palestine, Texas, Stati Uniti, 75801
- Palestine Regional Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
Screening Criteria
- Male or non-pregnant female ≥18 years of age
- Rutherford Clinical Category 2-4
- Clinical diagnosis of PAD requiring revascularization, secondary to atherosclerosis affecting a lower limb.
- Patient is willing to provide informed consent and comply with the required follow up visits Procedural Criteria
- De novo or nonstented restenotic lesions >90 days from prior angioplasty and/or atherectomy, at least 3 cm from any previously placed stent or vascular surgery site
- >70% diameter stenosis up to 15 cm in total length (with no greater than 3 cm length of contiguous intervening normal artery) in the superficial femoral and/or popliteal artery (between the profunda and tibioperoneal trunk)
- Reference vessel diameter ≥3mm and ≤ 8mm
- Successful wire crossing of lesion
- A patent artery proximal to the index lesion free from significant stenosis (significant stenosis is defined as >50% in iliac or >30% stenosis in common femoral artery) as confirmed by angiography (treatment of target lesion after successful treatment of iliac or common femoral artery lesions is acceptable)
Exclusion Criteria:
Screening Criteria
- Pregnant, nursing or planning on becoming pregnant in < 2years
- Life expectancy of <2 years
- Known active malignancy
- History of solid organ transplantation
- Patient actively participating in another investigational device or drug study
- History of hemorrhagic stroke within 3 months
- Previous or planned surgical or interventional procedure within 30 days of index procedure
- Chronic renal insufficiency with eGFR <29
- Prior bypass surgery, drug-coated balloon or stenting of the target lesion
- Contra-indication or known hypersensitivity to contrast media or physician prescribed antiplatelet regimen as applicable
- Systemic fungal infection
- Anticipated use of IIb/IIIa inhibitor prior to index lesion treatment
- Acute or sub-acute thrombus, acute vessel occlusion or sudden symptom onset
- Acute limb ischemia
- Inability to ambulate (e.g. from prior ipsilateral or contralateral amputation)
- Patient is receiving steroids already, however locally acting inhaled steroids for asthma treatment do not exclude patients from the trial Procedural Criteria
- Lesions extending into the trifurcation or above the profunda
- Heavy eccentric or moderate circumferential calcification at index lesion
- Lesion length is >15 cm as measured from proximal normal vessel to distal normal vessel, or there is no normal proximal arterial segment in which duplex ultrasound velocity ratios can be measured
- Inadequate distal outflow defined as absence of at least one patent tibial artery (no lesion >50% stenosis) with flow into the foot
- Use of adjunctive therapies other than angioplasty, atherectomy (mechanical or laser) or bare metal stenting (i.e. scoring/cutting balloon, drug-eluting stent, drug-coated balloon, cryoplasty, etc.)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Atherectomy
Up to 20 atherectomy procedures at up to 5 sites in the United States. Change in inflammatory biomarkers (hs-CRP, MCP-1 and MMP-9) from baseline to 24 hours post-procedure and 30-days post-revascularization procedure. This registry will also observe outcomes (target lesion revascularization rates, 6 and 12 month duplex ultrasound-detected binary restenosis with PSVR>2.4) post-atherectomy revascularization procedures. |
Device: Orbital or Directional or Laser Atherectomy Systems Atherectomy selection is driven by preference of the operator
|
|
Angioplasty
Up to 20 angioplasty procedures at up to 5 sites in the United States. Change in inflammatory biomarkers (hs-CRP, MCP-1 and MMP-9) from baseline to 24 hours post-procedure and 30-days post-revascularization procedure. This registry will also observe outcomes (target lesion revascularization rates, 6 and 12 month duplex ultrasound-detected binary restenosis with PSVR>2.4) post-angioplasty revascularization procedures. |
Device: Balloon Angioplasty Selection is driven by preference of the operator
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in inflammatory biomarkers
Lasso di tempo: Baseline to 24-hours post-procedure and 30-days post-procedure
|
Change in inflammatory biomarkers (hs-CRP, MCP-1 and MMP-9) from baseline to 24 hours post-procedure and 30-days post-revascularization procedure.
|
Baseline to 24-hours post-procedure and 30-days post-procedure
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Target Lesion Revascularization
Lasso di tempo: 6 and 12 months post-procedure
|
This registry will prospectively collect data from patients diagnosed with peripheral arterial disease to observe the restenosis rates in peripheral arteries compared with subjects enrolled in the DANCE trial (Mercator MedSystems TSP0149).
|
6 and 12 months post-procedure
|
|
Comparing biomarker (hs-CRP, MCP-1 and MMP-9) results
Lasso di tempo: Baseline to 24 hours post-procedure and 30-days post-revascularization procedure
|
This registry will prospectively collect data from patients diagnosed with peripheral arterial disease to observe the correlation between the levels of MCP-1, C-reactive protein and MMP-9 after angioplasty or atherectomy procedures in peripheral arteries compared with subjects enrolled in the DANCE trial (Mercator MedSystems TSP0149).
Objective measurement of biomarkers will be performed by a contract laboratory to avoid bias.
|
Baseline to 24 hours post-procedure and 30-days post-revascularization procedure
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Jason A Yoho, MD, Mission Research, New Braunfels, TX
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CIP0181
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Atherectomy System
-
Cardiovascular and Interventional Radiological...AbbottNon ancora reclutamentoIschemia minacciosa per gli arti cronici | Ischemia cronica minacciosa per gli arti
-
Ceric SàrlEuropean Cardiovascular Research Center; Philips Medical SystemsNon ancora reclutamentoMalattia coronarica stabile | Sindromi coronariche acute
-
Reciprocal LabsCalifornia HealthCare FoundationCompletato
-
Ahmed AbdullahCompletatoDolore, PostoperatorioPakistan
-
SpineSave AGReclutamentoSpondiloartrite | Instabilità colonna lombare | Spondilolistesi degenerativa | Stenosi spinale lombare degenerativa | Discopatia | Artrosi delle faccette articolariSvizzera
-
Nyra Medical, Inc.Non ancora reclutamentoRigurgito mitralico funzionale
-
Medtronic VascularReclutamentoMalattia cardiovascolare | Malattie vascolari | Ipertensione | Diabete mellito | Malattie renali cronicheOlanda, Belgio, Taiwan, Germania, Australia, Regno Unito, Malaysia, Irlanda
-
Gabi SmartCareCompletatoMalattia cardiovascolare | Malattia respiratoria | Malattia cardiaca | Difetto cardiaco congenito | Malattia infantile prematura | Malattia respiratoria cronica | Malattia cardiopolmonare cronicaStati Uniti, Belgio
-
Zealand University HospitalUniversity of Copenhagen; Technical University of Denmark; OptoCeuticsCompletatoMalattia di AlzheimerDanimarca
-
Chordate MedicalTerminato